Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 52

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 52
---
 of Board of Directors and the board proposes the participation in the purchase of a run -off insurance policy for the members of the Board of Directors, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for the current term of office until the next Ordinary Shareholders Meeting. 12.2. Approval of the Compensation for the Executive Officers The board proposes to adjust the compensation for the Company’s executive officers, due to the transactions contemplated by the Merger, to a new maximum aggregate amount of CHF 494,000 for the fixed compensation and a new maximum aggregate amount of CHF 2,206,000 for the variable compensation of the Company’s executive officers. Furthermore the board proposes to set the grant of equity or equity linked instruments at a maximum aggregate amount of CHF 991,000 for the compensation of the Company’s executive officers and the board proposes the participation in the purchase of a run -off insurance policy for the Company’s executive officers, to be effective at the time of the merger’s completion, with coverage amounts and terms to be approved by the Board of Directors, in each case for each of the financial year 2025 and the financial year 2026. 13. Approval of Contingent Value Rights (CVR) Agreement on an Advisory Basis The board proposes to approve the CVR Agreement in the sense of an advisory vote. The company intends to work towards selling its existing R&D assets under development, excluding the DOXA asset. 14. Approval of Option and RSU Conversion on an Advisory Basis The board proposes to approve the planned conversion of outstanding options and RSUs issued by Kadimastem into equivalent securities with identical rights in Company at the time of the completion of the transactions contemplated by the Merger Agreement in the sense of an advisory vote. Date Signature Signature, if held jointly To change the address on your account, please check the box at right and indicate your new address. * SPECIMEN * AC:ACCT9999 90.00 REFERENCES TO ADDITIONAL INFORMATION This proxy statement/prospectus incorporates important business and financial information about NLS that is not included in or delivered with this document. You may obtain this information without charge through the Securities and Exchange Commission (the “SEC”) website ( www.sec.gov) or upon your written or oral request by contacting the Chief Executive Officer of NLS Pharmaceutics Ltd., at The Circle6, 8058 Zurich, Switzerland, or by calling +